Drug intelligence / Profile preview

monepantel

Development stage
Phase 3
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

Monepantel is a small molecule anthelmintic belonging to the amino-acetonitrile derivative (AAD) class. It is primarily used in veterinary medicine for the treatment and control of gastrointestinal nematodes in sheep and cattle, including strains resistant to other anthelmintic classes[3][6]. Monepantel acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor subunits (notably ACR-23/MPTL‑1), leading to persistent activation, depolarization, paralysis, and death of susceptible nematodes[1][3][6]. The drug has minimal toxicity in mammals due to the absence of its molecular target in these species. Recently, monepantel has been investigated for repurposing as a treatment for amyotrophic lateral sclerosis (ALS), where it inhibits the mTOR signaling pathway involved in protein homeostasis[5].

Brand names
ZolvixZolvix Plus
Other names
N-(2-cyano-1-((2s)-5-cyano-2-(trifluoromethyl)phenoxy)propan-2-yl)-4-(trifluoromethylsulfanyl)benzamideBenzamide, n-((1s)-1-cyano-2-(5-cyano-2-(trifluoromethyl)phenoxy)-1-methylethyl)-4-((trifluoromethyl)thio)
02

Targets

Ode-P-nAChR (Oesophagostomum dentatum pyrantel/tribendimidine-sensitive nicotinic acetylcholine receptor)Asu-ACR-16 (Ascaris suum nicotinic acetylcholine receptor subunit ACR-16)ACR-23 (Nematode nicotinic acetylcholine receptor ACR-23)DEG-3/DES-2 nAChR (DEG-3/DES-2 nicotinic acetylcholine receptor)Ode-L-nAChR (Oesophagostomum dentatum levamisole-sensitive nicotinic acetylcholine receptor)

Beyond the preview

Go deeper on monepantel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on monepantel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call